All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA375)

NICE GUIDANCE ISSUED JANUARY 2016

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Adalimumab (Humira®)

For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate

Abbott Laboratories Ltd

March 2004

Adalimumab (Humira®) is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
Adalimumab (Humira®) was appraised at the AWMSG December 2003 meeting, where it was decided that treatment within NHS Wales should be supported with restrictions.
Restrictions identified included:

Adalimumab should only be available to physicians in secondary care specialising in rheumatology.

Adalimumab must be used in accordance with the British Society of Rheumatology guidelines for the use of anti-TNF agents.

Prescribers should be encouraged to report all suspected adverse reactions to adalimumab using the yellow card scheme.

See AWMSG December 2003 meeting minutes for further information.